Clinical Trials List
2024-10-01 - 2028-03-01
Phase I
Recruiting4
ICD-10C90.00
Multiple myeloma not having achieved remission
ICD-10C90.02
Multiple myeloma in relapse
ICD-10Z51.12
Encounter for antineoplastic immunotherapy
ICD-9203.00
Multiple myeloma, without mention of remission
-
Trial Applicant
Johnson & Johnson
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/02/01
Investigators and Locations
Co-Principal Investigator
- Che-Hung Lin Division of Hematology & Oncology
- 陳珈妤 Division of Hematology & Oncology
- 王幸婷 Division of Hematology & Oncology
- Chi-Ching Chen Division of Hematology & Oncology
- Chen-Yuan Lin Division of Hematology & Oncology
- 鄭富銘 Division of Hematology & Oncology
- Ming-Yu Lien Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Ya-Ping Chen Division of Hematology & Oncology
- Ya-Ting Hsu Division of Hematology & Oncology
- 張力常 Division of Hematology & Oncology
- 傅蓓安 Division of Hematology & Oncology
- Sin-Syue Li Division of Hematology & Oncology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Sheng-chieh Chou Division of General Internal Medicine
- 林耘曲 Division of General Internal Medicine
- MING YAO Division of General Internal Medicine
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
30 participants
-
Global
80 participants
